Preliminary scientific program of CEHC/CELD 2016

Ballroom-Classroom-2-w

23 June, 2016 AM

2nd MEETING OF CENTRAL EUROPEAN HEPATOLOGICAL COLLABORATION (CEHC)
(Open to all participants from Czech Republic, Hungary, Poland and Slovakia)

Sole supporter: IC-HEP – International Coalition of Hepatology Education Providers

9:30-9:40 Opening remarks

9:40 – 12:00 Collaborative research initiatives. Protocol proposals.
Chairs: Bela Hunyady (Hungary) and Robert Flisiak (Poland)

  • 9:40 – 10:00 Comparison of liver biopsy vs. elastography in staging liver fibrosis
    Peter Jarčuška 15 min + 5 min discussion
  • 10:00 – 10:20 Elastographic follow-up of patients treated with IFN-free versus IFN based regimens for HCV
    Gabor Horvath (Hungary) 15 min + 5 min discussion
  • 10:20 – 10:40 CAP in NAFLD/HCV
    Krzysztof Tomasiewicz (Poland) 15 min + 5 min discussion
  • 10:40 – 11:00 Long term efficacy after DAA based therapies
    Robert Flisiak (Poland) 15 min + 5 min discussion
  • 11:00 – 11:20 Collection of screening strategies and experience
    Michael Makara (Hungary) 15 min + 5 min discussion
  • 11:20 – 11:40 Long term follow-up of TVR/BOC containing triple regimens
    Bela Hunyady (Hungary) 15 min + 5 min discussion
  • 11:40 – 12:00 How to succeed in generating international disease registries?
    Peter Hegyi (Hungary) 15 min + 5 min discussion

12:00-13:00 Lunch break

23 June, 2016 PM /1

COST-EFFECTIVENESS IN LIVER DISORDERS (CELD) CONFERENCE

13:00 – 13:10 Opening of CELD

13:10 – 14:30 Methodology in health technology assessment
Chair: Imre Boncz (Hungary) and Gabor Horvath (Hungary)

  • 13:10 – 13:40 Basic concepts of health technology assessment
    Imre Boncz (Hungary)
  • 13:40 – 14:10 Cost-effectiveness assessment in liver diseases
    Guenka Petrova (Bulgaria)
  • 14:10 – 14:30 Discussion

23 June, 2016 PM /2

14:30-15:20 Cost-effectiveness issues in liver cirrhosis and genetic disorders of the liver
Chair: Ferenc Szalay (Hungary)

  • 14:30 – 14:50 Cost-effectiveness of terlipressin in the treatment of acute esophageal variceal bleeding
    Tamas Szamosi (Hungary)
  • 14:50-15:10 Financial aspects of management of Wilson’s disease and hemochromatosis
    Ferenc Szalay (Hungary)
  • 15:10-15:20 Discussion

15:20-15:40 Coffee break

23 June, 2016 PM /3

15:40-16:50 Free papers
Chairs: Bela Hunyady (Hungary), Istvan Tornai (Hungary)

  • 15:40-15:55 Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin treatment of hepatitis C genotype 1b infected patients after failure to previous first generation protease-inhibitor therapy. An interim analysis
    Bela Hunyady (Hungary)
  • 15:55-16:10 Prescribing in alcohol related liver disease- are we up to date with current guidelines?
    Tessa Hanley (UK)
  • 16:10-16:25 Economic burden of hepatitis B and C viruses infection in different stages of disease: A retrospective medical records based study from Southern of IranMohammadreza Fattahi (Iran)
  • 16:25-16:40 The Impact of Methadone Treatment on HCV/HIV prevalence among IDUs in Ukraine.
    Serhii Soloviov (Ukraine)
  • 16:40-16:50 Discussion

24 June, 2016 AM /1

08:30-10:30 How to finance real health care innovation in lower income European countries? – Part 1.
Chairs: Krzysztof Landa (Poland) and Zoltan Kalo (Hungary)

  • 08:30-09:00 How to finance real health care innovation in lower income European countries? The Polish example of HCV therapies.
    Krzysztof Landa (Poland)
  • 09:00-09:20 Reimbursement policies and achievements on the field of hepatology in Lithuania Kristina Garuoliene (Lithuania)
  • 09:20-09:40 Achievements in introduction of new HCV therapies in Hungary
    Judit Bidlo (Hungary)
  • 09:40-10:00 Importance of collaboration to find better solutions for the treatment of liver diseases
    Vladimir Zah (Serbia)
  • 10:00-10:10 Discussion

10:10-10:20 Coffee break

10:20-11:30 How to finance real health care innovation in lower income European countries? – Part 2.
Chairs: Krzysztof Landa (Poland) and Zoltan Kalo (Hungary)

  • 10:20-10:40 Reimbursement of innovative therapies for liver diseases in Slovenia Mitja Kos (Slovenia)
  • 10:40-11:00 Cure & Control of HCV in Romania Andrei Tarnea (Romania)
  • 11:00-11:20 Patients’ perspective on potential eradication of HCV in Central-Eastern Europe  Stanimir Hasurdjiev (Bulgaria)
  • 11:20-11:30 Discussion

24 June, 2016 AM /2

  • 11:30-12:30  ABBVIE SYMPOSIUM 60 min

12:30-13:30 Lunch break

24 June, 2016 PM /1

13:30 – 15:20 Cost-effectiveness issues in hepatitis C
Chairs: Geoffrey Dusheiko (UK) and Mihaly Makara (Hungary)

  • 13:30-14:00 Birth-cohort screening for HCV in Europe. Screening for HCV in acute IVD population and in HIV co-infected population. 
    Jean-Michel Pawlotsky (France)
  • 14:00-14:20 Risk-based screening versus other screening strategies for HCV – what is the optimal approach in Central-Easter Europe?
    Mihály Makara (Hungary)
  • 14:20-14:50 IFN-based/IFN-free treatment versus observation in CHC
    Geoffrey Dusheiko (UK)
  • 14:50-15:20 Cost-effectiveness issues in hepatitis C.
    Livio Garattini (Italy)
  • 15:20-15:40 Discussion

15:40-16:10 Coffee break

24 June, 2016 PM /2

16:10-18:00 Specific liver-disease related cost-effectiveness issues
Chairs: Peter Ferenci (Austria) and Robert Flisiak (Poland)

  • 16:10-16:40 Cost effectiveness analysis: who benefits: big pharma, payer or the patient?
    Peter Ferenci (Austria)
  • 16:40-17:10 Survillance for HCC in compensated or decompensated HBV cirrhosis
    Robert Flisiak (Bialystok, Poland)
  • 17:10-17:40 Survillance for HCC in non- cirrhotic CHB on NA treatment
    Vasily Isakov (Moscow, Russia)
  • 17:40-18:00 Discussion

24 June, 2016 PM /3

  • 17:10-18:10  GILEAD SYMPOSIUM

25 June, 2016 AM /1

08:30-10:00 Cost-effectiveness issues in hepatitis B
Chairs: Cihan Yurdaydin (Turkey) and Gabor Horvath (Hungary)

  • 08:30-09:00 Vaccination against HBV at birth versus at age 12. Vaccination against HBV in elderly people.
    Cihan Yurdaydin (Turkey)
  • 09:00-09:20 Entecavir versus tenofovir in compensated or decompensated HBV cirrhosis
  • 09:20-09:40 IFN versus NA for HBV in non-cirrhotic patients
    Krzysztof Tomasiewicz (Poland)
  • 09:40-10:00 Annual versus six-monthly follow up of HBV-DNA during long term NA therapy
    Istvan Tornai (Hungary)
  • 10:00-10:20 Discussion

10:20-10:40 Coffee break

25 June, 2016 AM /2

10:40-12:40 Treatment of HCV in Central-Eastern-Southern Europe.
Chairs: Cihan Yurdaydin (Turkey) and Jean-Michel Pawlotzky (UK)

  • 10:40-11:00 Treatment of hepatitis C in Slovenia.
    Mojca Matičič (Slovenia)
  • 11:00-11:20 Real World Data in Treating HCV – Amethyst Cohort, Bulgaria
    Krasimir Antonov (Bulgaria)
  • 11:20-11:40 Real World Data from AMBER study
    Robert Flisiak (Poland)
  • 11:40-12:00 Real life data for patients with HCV in Romania
    Anca Streinu Cercel (Romania)
  • 12:00-12:20 The cost analysis of HCV treatment in Ukraine
    Olha Zalis’ka (Ukraine)

12:40-13:00 Closing remarks

 

Download in pdf >>